Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

IPF World Week

- PMLiVE

Two drugs found to reduce mortality in severe COVID-19 patients

Actemra and Kevzara also improved recovery times among critically ill COVID-19 patients

- PMLiVE

Roche’s tiragolumab plus Tecentriq combo wins FDA breakthrough therapy designation

Swiss pharma is aiming for approval in first-line NSCLC

Roche Basel Switzerland

Roche gets EU approval for fixed-dose Herceptin/Perjeta combination

Treatment can be administered as an injection instead of an intravenous infusion

Roche Basel Switzerland

Roche’s Xofluza pill wins FDA approval for post-exposure flu prevention

First single-dose flu medication approved for post-exposure prophylaxis

Roche Basel Switzerland

Roche’s flu pill Xofluza moves closer towards EU approval

CHMP recommends drug for approval in the EU

Visual Storytelling in HealthTech

Rodney Hu, founder of 209|Digital and a popular podcast host. We explore Rodney’s work within the HealthTech space and what he believes has to happen for the healthcare industry to more...

Impetus Digital

- PMLiVE

Roche and Atea link up for oral COVID-19 drug; UK to test coronavirus vaccine T cell responses

New developments for COVID-19 treatments and vaccines

- PMLiVE

Roche and Prothena set to advance Parkinson’s disease candidate into phase 2b

Drug moves into late-stage testing despite failing to hit primary endpoint in previous trial

- PMLiVE

Roche to collaborate with Dyno on gene therapies for CNS/liver diseases

Dyno will use its CapsidMap platform to develop novel AAV vectors for improved gene therapies

Courageous Conversation ep.9: Elon Musk’s Neuralink and the Future of the Computer Brain Interface

Natalie Yeadon, Co-Owner and Managing Director at Impetus Digital, provides insight on Elon Musk's Neuralink and the Future of the Computer Brain Interface.

Impetus Digital

- PMLiVE

Roche’s Ocrevus boasts positive long-term data in MS

After two years of treatment 75% of patients had no evidence of disease activity

- PMLiVE

New medical communications agency BOLDSCIENCE launches

The new global agency boldly sets out its plans to become a major player in med comms

BOLDSCIENCE

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links